Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolor Biotech has signed a definite agreement with Yeda Research and Development in connection with a novel technology that is used to develop therapeutic peptide and small molecules, Reversible PEGylation.
Subscribe to our email newsletter
Under a limited option-to-license agreement from Yeda, Prolor has been developing oxyntomodulin peptide, a drug compound using this technology as a treatment of obesity and has now exercised its option to license the technology.
Prolor chairman Phillip Frost said this license from the prestigious Weizmann Institute of Science represents an exciting opportunity for Prolor.
"It complements our core platform and expands our pipeline of competitive therapeutic drug candidates to include new, important clinical indications," Frost said.